BRD4 and ovarian cancer: The pharmacological inhibition of BRD4 with BET inhibitors (BETis) JQ1 and I-BET151 substantially abrogated both the in vitro growth and in vivo tumorigenesis of ovarian cancer [23], and BRD4 inhibitors have been largely used in several pre-clinical studies in ovarian cancer [25,26,27].